ClinicalTrials.gg
TerminatedNCT01891643Updated Jul 1, 2021Results posted

PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)

A Phase 3 interventional study of Lenalidomide and Dexamethasone in Newly Diagnosed, Previously Untreated Multiple Myeloma, sponsored by Bristol-Myers Squibb. Terminated at 14 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-01.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Basic science

Why this study was terminated
Insufficient enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 249 studies testing lenalidomide in Multiple Myeloma — 29 open to participants now, 70 under way, 14 of them phase 3. Lenalidomide · Multiple Myeloma.

Enrollment
184th of 249
23 · median 50
Started
2013
with 14 others
Phase 3
44 of 249
3 open now
Registered
116th of 249
by date

Among the 249 studies testing lenalidomide in Multiple Myeloma, this one is the 184th largest by enrollment, is one of 15 that started in 2013, is one of 44 in phase 3, and was the 116th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

29 of the 249 studies testing lenalidomide in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 249 studies testing lenalidomide in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of the study is to look at subjects who receive Lenalidomide, Dexamethasone, and Elotuzumab and determine if they will have lower surface CS1 expression on malignant plasma cells at the time of progression than those who receive Lenalidomide and Dexamethasone without Elotuzumab

03

Conditions studied

  • Newly Diagnosed, Previously Untreated Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion criteria

Inclusion Criteria:

Subjects who are newly diagnosed with symptomatic MM and who:

  • Have not received any prior systemic anti-myeloma therapy
  • Have
  • And are not candidates for high-dose therapy plus stem-cell transplantation (SCT) because of age (≥65 years) or coexisting conditions. Refusal to undergo high dose therapy with SCT is NOT sufficient for entry onto CA204-006 for a subject \<65 years old. There must be a comorbidity that prevents SCT for a subject \<65 years old

Exclusion criteria

Exclusion Criteria:

  • Subjects with non-secretory or oligo-secretory or free light-chain only myeloma
  • Smoldering MM, defined as asymptomatic MM with absence of lytic bone lesions
  • Monoclonal Gammopathy of Undetermined Significance (MGUS)
  • Active plasma cell leukemia
  • Known (HIV) infection or active hepatitis A, B, or C
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Arm 1: Lenalidomide + Dexamethasone

    Lenalidomide 25 mg capsules by mouth once daily (on Days 1-21), repeat every 28 days until subject meets criteria for discontinuation of study drug Dexamethasone 40 mg tablets by mouth weekly (on Days 1, 8, 15, 22), repeat every 28 days until subject meets criteria for discontinuation of study drug

    Drug: Lenalidomide · Drug: Dexamethasone

  • Experimental
    Arm 2: Lenalidomide + Dexamethasone + Elotuzumab

    Lenalidomide 25 mg capsules by mouth once daily (Days 1-21) Dexamethasone 28 mg tablets by mouth once daily \[Days 1, 8, 15, 22 (cycles 1 \& 2); Days 1 \& 15(cycles 3-18); Day 1 (cycle 19 \& beyond)\] Dexamethasone 40 mg tablets by mouth once daily \[Days 8 \& 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 \& beyond)\] Dexamethasone 8 mg IV (intravenous) solution once daily \[Days 1, 8, 15, 22 (cycles 1 \& 2); Days 1 \& 15 (cycles 3-18); Day 1 (cycle 19 \& beyond)\] Elotuzumab 10 mg/kg IV solution weekly \[Days 1, 8, 15, 22 (cycles 1 \& 2); Days 1 \& 15 (cycles 3-18)\] Elotuzumab 20 mg/kg IV solution on Day 1 (cycle 19 \& beyond) Repeat above-mentioned dose cycles every 28 days until subject meets criteria for discontinuation of study drug

    Drug: Lenalidomide · Drug: Dexamethasone · Biological: Elotuzumab

Interventions

  • Also known as: Revlimid®

  • Also known as: Decadron®, Dexamethasone Intensol®, Dexpak®, Taperpak®

  • BiologicalElotuzumab

    Also known as: BMS-901608

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Progression of the Cell Surface Expression of CS1 From Bone Marrow-Derived Multiple Myeloma (MM) Cells

    CS1 (CD2 subset-1, also known as CRACC, SLAMF7, CD319) expression levels in multiple myeloma cells were analyzed from bone-marrow aspirates collected at baseline and at time of progression through mean fluorescent intensity. The following conditions were considered to describe multiple myeloma cells expressing CS1 (CS1+/CD38++/CD138+/CD56+/CD19-/CD45DIM)

    Time frame: From baseline (screening) to time of progression (up to approximately 54 months)

Secondary outcomes

  1. Percent of Bone Marrow-Derived Multiple Myeloma (MM) Cells Expressing Cell Surface CS1 at Time of Progression

    CS1 (CD2 subset-1, also known as CRACC, SLAMF7, CD319) expression levels in multiple myeloma cells were analyzed from bone-marrow aspirates collected at time of progression. The following conditions were considered to describe multiple myeloma cells expressing CS1 (CS1+/CD38++/CD138+/CD56+/CD19-/CD45DIM)

    Time frame: Time of progression (up to approximately 54 months from pre-treatment screening)

  2. Levels of CS1 Soluble Form (sCS1) in Serum

    Expression levels of the free form of soluble CS1 were analyzed at different timepoints from serum samples derived from peripheral blood collection

    Time frame: At baseline (screening), during main study therapy (cycle 3 day 1, up to 64 days) and at time of progression (up to approximately 31 months)

  3. Change From Baseline in the Levels of CS1 Soluble Form (sCS1) in Serum During Therapy and At Progression

    Expression levels of the free form of soluble CS1 were analyzed at different timepoints from serum samples derived from peripheral blood collection

    Time frame: From baseline (screening) to cycle 3 day 1 of the main study therapy (up to 64 days) and from baseline (screening) to time of progression (up to approximately 31 months)

  4. Change From Baseline in the Number of Circulating Multiple Myeloma (MM) Cells

    Circulating MM cells isolated from peripheral blood

    Time frame: From baseline (screening) to cycle 3 day 1 of the main study therapy (up to 64 days) and from baseline (screening) to the time of progression (up to approximately 54 months)

  5. Change From Baseline in Cell Surface CS1 Expression Levels in Circulating Multiple Myeloma (MM) Cells

    Circulating MM cells isolated from peripheral blood

    Time frame: From baseline (screening) to cycle 3 day 1 of the main study therapy (up to 64 days) and from baseline (screening) to the time of progression (up to approximately 54 months)

  6. CS1 Expression Levels in Matched Samples of Bone Marrow-Derived Multiple Myeloma (MM) Cells and Circulating MM Cells

    CS1 expression levels analyzed from matching bone marrow aspirates (for bone marrow-derived MM cells) and from peripheral blood (for circulating tumor cells) collected from the same participants

    Time frame: At baseline (screening), during main study therapy (cycle 3 day 1) and at time of progression (up to approximately 54 months)

07

Results

Posted Jul 1, 2021

Participant flow

Participant flow — Overall Study
MilestoneE-Ld CohortLd Cohort
Started1310
Completed30
Not completed1010
Withdrew: Adverse event unrelated to study drug25
Withdrew: Disease progression43
Withdrew: Study drug toxicity30
Withdrew: Maximum clinical benefit01
Withdrew: Poor/non-compliance01
Withdrew: Participant request to discontinue10

Outcome measures

PrimaryChange From Baseline to Progression of the Cell Surface Expression of CS1 From Bone Marrow-Derived Multiple Myeloma (MM) Cells

CS1 (CD2 subset-1, also known as CRACC, SLAMF7, CD319) expression levels in multiple myeloma cells were analyzed from bone-marrow aspirates collected at baseline and at time of progression through mean fluorescent intensity. The following conditions were considered to describe multiple myeloma cells expressing CS1 (CS1+/CD38++/CD138+/CD56+/CD19-/CD45DIM)

Time frame:
From baseline (screening) to time of progression (up to approximately 54 months)

No measurements were reported for this outcome.

SecondaryPercent of Bone Marrow-Derived Multiple Myeloma (MM) Cells Expressing Cell Surface CS1 at Time of Progression

CS1 (CD2 subset-1, also known as CRACC, SLAMF7, CD319) expression levels in multiple myeloma cells were analyzed from bone-marrow aspirates collected at time of progression. The following conditions were considered to describe multiple myeloma cells expressing CS1 (CS1+/CD38++/CD138+/CD56+/CD19-/CD45DIM)

Time frame:
Time of progression (up to approximately 54 months from pre-treatment screening)
Reported as:
Median · Percent of cells expressing CS1
Percent of Bone Marrow-Derived Multiple Myeloma (MM) Cells Expressing Cell Surface CS1 at Time of Progression
Percent of cells expressing CS1E-Ld CohortLd Cohort
Percent of Bone Marrow-Derived Multiple Myeloma (MM) Cells Expressing Cell Surface CS1 at Time of Progression46.59 (0.0 to 99.1)84.62 (NA to NA)
SecondaryLevels of CS1 Soluble Form (sCS1) in Serum

Expression levels of the free form of soluble CS1 were analyzed at different timepoints from serum samples derived from peripheral blood collection

Time frame:
At baseline (screening), during main study therapy (cycle 3 day 1, up to 64 days) and at time of progression (up to approximately 31 months)
Reported as:
Median · ug/L
Levels of CS1 Soluble Form (sCS1) in Serum
ug/LE-Ld CohortLd Cohort
Baseline3.60 (0.7 to 7.4)13.27 (2.2 to 79.8)
Cycle 3 day 1 of main study therapy0.15 (0.1 to 0.3)0.72 (0.2 to 3.0)
Time of progression0.39 (0.2 to 0.5)49.85 (NA to NA)
SecondaryChange From Baseline in the Levels of CS1 Soluble Form (sCS1) in Serum During Therapy and At Progression

Expression levels of the free form of soluble CS1 were analyzed at different timepoints from serum samples derived from peripheral blood collection

Time frame:
From baseline (screening) to cycle 3 day 1 of the main study therapy (up to 64 days) and from baseline (screening) to time of progression (up to approximately 31 months)
Reported as:
Median · ug/L
Change From Baseline in the Levels of CS1 Soluble Form (sCS1) in Serum During Therapy and At Progression
ug/LE-Ld CohortLd Cohort
From baseline to Cycle 3 day 1 of main study therapy-3.51 (-6.9 to -0.6)-4.08 (-15.1 to -1.6)
From baseline to time of progression-0.85 (-6.9 to -0.4)-17.41 (NA to NA)
SecondaryChange From Baseline in the Number of Circulating Multiple Myeloma (MM) Cells

Circulating MM cells isolated from peripheral blood

Time frame:
From baseline (screening) to cycle 3 day 1 of the main study therapy (up to 64 days) and from baseline (screening) to the time of progression (up to approximately 54 months)

No measurements were reported for this outcome.

SecondaryChange From Baseline in Cell Surface CS1 Expression Levels in Circulating Multiple Myeloma (MM) Cells

Circulating MM cells isolated from peripheral blood

Time frame:
From baseline (screening) to cycle 3 day 1 of the main study therapy (up to 64 days) and from baseline (screening) to the time of progression (up to approximately 54 months)

No measurements were reported for this outcome.

SecondaryCS1 Expression Levels in Matched Samples of Bone Marrow-Derived Multiple Myeloma (MM) Cells and Circulating MM Cells

CS1 expression levels analyzed from matching bone marrow aspirates (for bone marrow-derived MM cells) and from peripheral blood (for circulating tumor cells) collected from the same participants

Time frame:
At baseline (screening), during main study therapy (cycle 3 day 1) and at time of progression (up to approximately 54 months)

No measurements were reported for this outcome.

Adverse events

Collected over From first dose to 60 days following last dose (up to approximately 80 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
E-Ld Cohort8/13 (61.5%)9/13 (69.2%)13/13 (100%)
Ld Cohort5/10 (50%)7/10 (70%)10/10 (100%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventE-Ld CohortLd Cohort
PneumoniaInfections and infestations1/132/10
Femur fractureInjury, poisoning and procedural complications0/132/10
AnaemiaBlood and lymphatic system disorders1/131/10
Sinus tachycardiaCardiac disorders0/131/10
CataractEye disorders1/131/10
Multiple organ dysfunction syndromeGeneral disorders0/131/10
BronchitisInfections and infestations1/131/10
Electrolyte imbalanceMetabolism and nutrition disorders0/131/10
Acute lymphocytic leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/131/10
Transient ischaemic attackNervous system disorders0/131/10
Most frequent other events
Showing 10 of 147
Most frequent other events
EventE-Ld CohortLd Cohort
AnaemiaBlood and lymphatic system disorders3/136/10
DiarrhoeaGastrointestinal disorders5/136/10
Oedema peripheralGeneral disorders2/135/10
FatigueGeneral disorders6/132/10
Back painMusculoskeletal and connective tissue disorders2/134/10
ConstipationGastrointestinal disorders4/133/10
RashSkin and subcutaneous tissue disorders4/131/10
NauseaGastrointestinal disorders2/133/10
PyrexiaGeneral disorders1/133/10
HypokalaemiaMetabolism and nutrition disorders1/133/10

Baseline characteristics

Age, Continuous
Age, Continuous(Years)E-Ld CohortLd CohortTotal
Mean74.8 ± 6.7771.3 ± 6.5373.3 ± 6.75
Sex: Female, Male
Sex: Female, Male(Participants)E-Ld CohortLd CohortTotal
Female6612
Male7411
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)E-Ld CohortLd CohortTotal
Hispanic or Latino000
Not Hispanic or Latino235
Unknown or Not Reported11718
Race (NIH/OMB)
Race (NIH/OMB)(Participants)E-Ld CohortLd CohortTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American112
White12921
More than one race000
Unknown or Not Reported000
08

Study locations

14 sites
  • Pacific Hematology Oncology Associates
    San Francisco, California 94115, United States
  • Memorial Cancer Institute
    Hollywood, Florida 33021, United States
  • Illinois Cancercare, Pc
    Peoria, Illinois 61615, United States
  • Franciscan St. Francis Health
    Indianapolis, Indiana 46237, United States
  • Crescent City Research Consortium, LLC
    Marrero, Louisiana 70072, United States
  • Ohio State University Medical Center
    Columbus, Ohio 43210, United States
  • Medical University Of South Carolina Hollings Cancer Center
    Charleston, South Carolina 29425, United States
  • Baptist Cancer Center
    Memphis, Tennessee 38120, United States
  • Northern Utah Associates
    Ogden, Utah 84405, United States
  • Local Institution
    Athens, 11528, Greece
  • Local Institution
    Genova, 16132, Italy
  • Local Institution
    Rome, 00161, Italy
  • Local Institution
    Chorzow, 41-500, Poland
  • Local Institution
    Lublin, 20-081, Poland
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2013 to primary completion in Jun 2020, 80 months.

Results were first posted in Jul 2021, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2013
First posted
Jul 3, 2013
StartActual
Sep 30, 2013
Primary completionActual
Jun 25, 2020
CompletionActual
Jun 25, 2020
Results first posted
Jul 1, 2021
Last update
Jul 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01891643
Collaborators
Abbott
Responsible party
Sponsor
First posted
Jul 3, 2013
Start date
Sep 30, 2013
Primary completion
Jun 25, 2020
Completion
Jun 25, 2020
Results posted
Jul 1, 2021
Last update
Jul 1, 2021

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lenalidomide · Dexamethasone

Start the discussion